Zelira Therapeutics (AU:ZLD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zelira Therapeutics has received the third tranche of funding, totaling US$681k, for its HOPE® 1 clinical trials from the 2011 Forman Trust, bringing the total SPV funding to US$2.569 million. The company has also secured significant patents for its HOPE® formulations in the treatment of Autism Spectrum Disorder and received a A$919k R&D Tax Incentive refund, which will be used to advance its clinical development programs. Additionally, Zelira is advancing the transformation of Zenivol® into a capsule form and preparing for FDA submissions, with a pre-IND meeting successfully held post-quarter.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.